Skip Ribbon Commands
Skip to main content
A- A A+

Find a Doctor

Dr Elaine Coustan-Smith

  • Principal Research Scientist, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore (Research Specialty: Haematology, Oncology & Blood/Marrow Transplantation)
Specialty in Immunology, Nottingham Trent University (UK), FIBMS, Specialty in Haematology, Sheffield Hallam University (UK), ASCP (QCYM), American Society for Clinical Pathology Board of Registry


​Before moving to Singapore in 2011, Ms Elaine Coustan-Smith was the Laboratory Manager in the Department of Oncology at St Jude Children’s Research Hospital in Memphis, Tennessee. Prior to that, she was the Chief Medical Laboratory Scientific Officer in the Department of Immunology at the Royal Free Hospital, London. 


  • Invited speaker and workshop organiser at more than 20 conferences worldwide
  • Responsible for the laboratory training of 85 visiting students and scientists from 38 countries


Journals & Publications

  1. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, … Campana D (1998). Immunologic detection of minimal residual disease in children with acute lymphoblastic leukemia. Lancet, 351(9102):550-4.
  2. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, … Campana D (2000). Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 96(8):2691-6..
  3. Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S, … Campana D (2003). Clinical significance of residual disease during treatment in childhood acute myeloid leukemia. British Journal of Haematology, 123(2):243-52.
  4. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, … Campana D (2009). Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. The Lancet. Oncology., 10(2):147-56. doi: 10.1016/S1470-2045(08)70314-0
  5. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Coustan-Smith E, … Campana D (2010). Minimal residual disease–directed therapy for childhood acute myeloid leukemia: results of the AML02 Multicenter Trial. The Lancet. Oncology., 11(6):543-52. doi: 10.1016/S1470-2045(10)70090-5
  6. Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, … Campana D (2011). New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood, 117(23):6267-76. doi: 10.1182/blood-2010-12-324004
  7. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, … Coustan-Smith E (2012). The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature, 481(7380):157-63. doi: 10.1038/nature10725
  8. Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY, … Campana D (2012). Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 30(29):3625-32. doi: 10.1200/JCO.2011.41.5323
  9. Faham M, Zheng J, Moorhead M, Carlton V, Stow P, Coustan-Smith E, … Campana D (2012). Deep sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood, 120(26):5173-80. doi: 10.1182/blood-2012-07-444042
  10. Wright KD1, Onciu MM, Coustan-Smith E, Campana D, Raimondi C, Hiroto H, … Sandlund JT (2013). Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia. Pediatric Blood & Cancer, 60(7):E38-41. doi: 10.1002/pbc.24483
  11. Coustan-Smith E, Campana, D (2013). Should evaluation for minimal residual disease be routine in acute myeloid leukemia? Current Opinion in Hematology, Lippincott, Williams & Wilkins, 20(2): 86-92. 
  12. Jeha S, Coustan-Smith E, Pei D, Sandlund JT, Rubnitz JE, Howard SC, … Campana D (2014). Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer, 120(10):1514-9. doi: 10.1002/cncr.28598
  13. Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, Coustan-Smith E, … Campana D (2014). Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound Interleukin 15. Blood, 124(7):1081-8. doi: 10.1182/blood-2014-02-556837
  14. Karol SE, Coustan-Smith E, Cao X, Shurtleff SA, Raimondi SC, Choi JK, … Inaba H (2014). Prognostic factors in children with acute myeloid leukemia and excellent response to remission induction therapy. British Journal of Haematology, 168(1):94-101. doi: 10.1111/bjh.13107
  15. Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, … Campana D (2015). Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukemia: a prospective study. The Lancet. Oncology., 16(4):465-74. doi: 10.1016/S1470-2045(15)70082-3
  16. Mullighan CG, Jeha S, Pei D, Payne-Turner D, Coustan-Smith E, Roberts KG, … Pui CH (2015). Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood, 126(26):2896-9. doi: 10.1182/blood-2015-09-671131
  17. Shimasaki N, Coustan-Smith E, Kamiya T, Campana D (2016). Expanded and armed natural killer cells for cancer treatment. Cytotherapy, 18(11):1422-1434. doi: 10.1016/j.jcyt.2016.06.013
  18. Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha S, Cheng C, … Campana D (2015). Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia, 31(2):333-339. doi: 10.1038/leu.2016.234
  19. Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Coustan-Smith E, … Gamis AS (2017). Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood, 129(25):3304-3313. doi: 10.1182/blood-2017-01-764324  
  20. Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D (2017). Blockade of CD7 expression in T cells for effective chimeric antigen-receptor targeting of T-cell malignancies. Blood Advances, 1(25):2348-2360. doi: 10.1182/bloodadvances.2017009928


Back to Top